A McCabe

Alison Munro

AU Buzdar

B Seruga

Brian Z Ring

BZ Ring

C Desmedt

C Sotiriou

CM Perou

CW Elston

David A Cameron

Douglas T Ross

DT Ross

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

Fiona M Campbell

Gillian R Kerr

Hans Christian Pedersen

Ian H Kunkler

Jeremy Thomas

JMS Bartlett

John MS Bartlett

JS Thomas

L Hughes-Davies

Laura Johnstone

LJ van't Veer

PM Ravdin

RC Coombes

RL Camp

Robert S Seitz

Rodney A Beck

S Paik

S Pancholi

Udi Chetty

Wilma Jack

English

PubMed

Introduction: Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat (R) test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up.Methods: Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy were collected following appropriate ethical review. Of 1,390 cases stained, 197 received no adjuvant hormonal or chemotherapy, 1,044 received tamoxifen only, and 149 received a combination of hormonal therapy and chemotherapy. Median age at diagnosis was 57, 71% were postmenopausal, 23.9% were node-positive and median tumor size was 1.5 cm. Samples were stained using triplicate 0.6 mm(2) tissue microarray cores, and positivity for p53, HTF9C, CEACAM5, NDRG1 and SLC7A5 was assessed. Each case was assigned a Mammostrat (R) risk score, and distant recurrence-free survival (DRFS), relapse-free survival (RFS) and overall survival (OS) were analyzed by marker positivity and risk score.Results: Increased Mammostrat (R) scores were significantly associated with reduced DRFS, RFS and OS in estrogen receptor (ER)-positive breast cancer (P &lt; 0.00001). In multivariate analyses the risk score was independent of conventional risk factors for DRFS, RFS and OS (P &lt; 0.05). In node-negative, tamoxifen-treated patients, 10-year recurrence rates were 7.6 +/- 1.5% in the low-risk group versus 20.0 +/- 4.4% in the high-risk group. Further, exploratory analyses revealed associations with outcome in both ER-negative and untreated patients.Conclusions: This is the fifth independent study providing evidence that Mammostrat (R) can act as an independent prognostic tool for ER-positive, tamoxifen-treated breast cancer. In addition, this study revealed for the first time a possible association with outcome regardless of node status and ER-negative tumors. When viewed in the context of previous results, these data provide further support for this antibody panel as an aid to patient management in early-stage breast cancer.</p

Bartlett, John M S

Thomas, Jeremy

Ross, Douglas T

Seitz, Robert S

Ring, Brian Z

Beck, Rodney A

Pedersen, Hans Christian

Munro, Alison

Kunkler, Ian

Campbell, Fiona M

Jack, Wilma

Kerr, Gillian R

Johnstone, Laura

Cameron, David A

Chetty, Udi

Edinburgh Research Explorer

Mammostrat (R) as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

Springer - Publisher Connector

Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

Crossref

Adjuvant! Version 5. Underlying data and assumptions. Breast Cancer Res Treat

Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet

DL: Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.

DL: Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res

DT: Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.

EP: Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

JM: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

JMS: Histological grading of invasive breast carcinoma - a simplification of existing methods in a large conservation series with long-term follow-up. Histopathology

K: A UK NEQAS ring study evaluating observer variation in the diagnosis of HER2 amplification using the Kreatech (TM) HER2 FISH probe. Cancer Res

Molecular portraits of human breast tumours. Nature

Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol

SH: Gene expression profiling predicts clinical outcome of breast cancer.

Sotiriou C: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res

Tamoxifen: the drug that came in from the cold.

Tannock IF: Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes.

When should I start using a new biomarker: Focus on Expression arrays (vol 5, pg 97,

Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer.

Wolmark N: Chemosensitivity and stratification by a five Bartlett et al.

file:///data/core-remote/dit/data/Springer-OA/pdf/0ae/aHR0cDovL2xpbmsuc3ByaW5nZXIuY29tLzEwLjExODYvYmNyMjYwNC5wZGY=.pdf

Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

Abstract

Similar works

Full text

Available Versions

Edinburgh Research Explorer

Springer - Publisher Connector

Crossref